Celularity Inc.
CELU
Rank in Stocks
#25649
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to... Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Share Price
$0.7597
Last synced: 2026-11-09
Market Cap
$24.65M
Change (1 day)
-0.05%
Change (1 year)
-55.83%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Celularity Inc. (CELU)
Category
Healthcare
EPS for Celularity Inc. (CELU)
EPS as of June 2026 TTM: $-1.79
According to Celularity Inc.'s latest financial reports, its current EPS (TTM) is $-1.79. At the end of 2025 the company had an EPS of $-3.59, a decrease compared to its 2024 EPS of $-2.64.
EPS history for Celularity Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.79 | -50.14% |
| 2025 | $-3.59 | 35.75% |
| 2024 | $-2.64 | -76.00% |
| 2023 | $-11.02 | -1,186.33% |
| 2022 | $1.01 | -112.89% |
| 2021 | $-7.87 | -93.04% |
| 2020 | $-113.06 | 27.39% |
| 2019 | $-88.75 | 0.00% |
| 2018 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -974.86% |
US
|
|
| $-7.07 | 294.97% |
US
|
|
| $-5.29 | 195.53% |
AU
|
|
| $12.88 | -819.56% |
BE
|
|
| $21.56 | -1,304.47% |
NL
|
Questions about Celularity Inc.'s earnings per share (EPS)
What is Celularity Inc.'s earnings per share (EPS)?
Celularity Inc.'s earnings per share (EPS) over the last twelve months is $-1.79, as of Jun 2026.
What was Celularity Inc.'s earnings per share (EPS) in 2025?
In 2025, Celularity Inc.'s earnings per share (EPS) was $-3.59, compared with $-2.64 in 2024.
How has Celularity Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Celularity Inc.'s earnings per share (EPS) was highest in 2022 ($1.01) and lowest in 2020 ($-113.06).
How does Celularity Inc.'s earnings per share (EPS) compare with similar companies?
Celularity Inc.'s earnings per share (EPS) ($-1.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.